Summary RegeneRx Biopharmaceuticals Inc (RegeneRx) is a clinical-stage biopharmaceutical company that designs, researches and develops novel peptides targeted at diseases with unmet medical needs.The company offers clinical trials, science and discovery and business development services.
Its business development services include clinical development and commercialization interests in desired pharmaceutical therapeutic fields for suitable infrastructure, expertise and a long-term initiative in disease areas.RegeneRx’s research areas include neurologic and stroke; cytoskeletal research; renal disease, renal organogenesis and fibrosis; dermal scarring, stem cell, cardiovascular reperfusion injury, ophthalmic mechanisms of repair, cosmeceuticals, burns and pulmonary arterial hypertension.
The company conducts research and development on novel pharmaceuticals, which protect and repair tissue and organ damage.It collaborates with universities, hospitals, and medical research institutions worldwide.
RegeneRx is headquartered in Rockville, Maryland, the US.
RegeneRx Biopharmaceuticals Inc (RGRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Macular Edema - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H1 2020, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape. Macular edema is swelling or fluid retention in a specialized...
The benefits offered by membrane chromatography over conventional chromatography methods are expected to drive the overall growth of the membrane chromatography market. The membrane chromatography market is estimated to grow from USD 198 million in 2020 to USD 408 million by 2025, at a CAGR of 15.5% during the forecast period. The major...
The North America bioreactors market is expected to reach US$ 2,102.75 Mn by 2027 from US$ 1,188.50 Mn in 2019. The market is estimated to grow at a CAGR of 7.5% during 2020-2027.The bioreactorsmarketis growing primarily due to the increasing adoption of single-use bioreactors and rising demand of bioreactors by biopharmaceutical and biotechnology...
The Global Cancer Monoclonal Antibody Partnering 2014-2020: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer monoclonal antibody partnering...
Erythropoietin Drugs Market Research Report by Drug Class (Biologics and Biosimilars), by Product (Darbepoetin-alfa, Epoetin-alfa, and Epoetin-beta), by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Erythropoietin Drugs Market is expected to grow from USD 6,157.17 Million in 2019 to...
176 pages •
By Global Industry Analysts
• Jul 2020
Global 3D Cell Culture Market to Reach $3.5 Billion by 2027 Amid the COVID-19 crisis, the global market for 3D Cell Culture estimated at US$968.6 Million in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 20.2% over the analysis period 2020-2027. Cancer & Stem Cell Research, one of...
Increasing incidence of chronic diseases, and government investments for cell-based research are set to drive the cell expansion market.’’ The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%. Growth in this market is largely driven by the increasing...